Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Autologous Hematopoietic Stem Cell Transplant Recipient”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Not applicableStudy completedNCT01111201
What this trial is testing

International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients

Who this might be right for
Breast CancerLymphoma
Memorial Sloan Kettering Cancer Center 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT02420860
What this trial is testing

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Hematopoietic Cell Transplantation RecipientPlasma Cell Myeloma
M.D. Anderson Cancer Center 113
Not applicableStudy completedNCT03659773
What this trial is testing

Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

Who this might be right for
VaccinationHematopoietic Stem Cells
Hospices Civils de Lyon 152
Testing effectiveness (Phase 2)Study completedNCT00509938
What this trial is testing

Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients

Who this might be right for
Hematopoietic Stem Cell TransplantationBacterial Infections and Mycoses
AM-Pharma 8
Not applicableUnknownNCT04024618
What this trial is testing

Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients

Who this might be right for
Malignant Hematologic Neoplasm
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 40
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Early research (Phase 1)Study completedNCT01163357
What this trial is testing

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Who this might be right for
Autologous Hematopoietic Stem Cell Transplant RecipientLoss of Chromosome 17pPlasma Cell Leukemia+2 more
City of Hope Medical Center 18
Testing effectiveness (Phase 2)WithdrawnNCT03328936
What this trial is testing

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Ohio State University Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01718743
What this trial is testing

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Hematopoietic Cell Transplantation RecipientPlasma Cell Myeloma
M.D. Anderson Cancer Center 64
Testing effectiveness (Phase 2)Study completedNCT02210065
What this trial is testing

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

Who this might be right for
LeukemiaLymphoma
M.D. Anderson Cancer Center 6